FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Human Drugs

9 Observations in Staska Pharmaceuticals FDA-483

FDA releases the form FDA-483 with nine observations from an inspection at the Staska Pharmaceuticals outsourcing facility in Bennet, NE.

latest-news-card-1
Human Drugs

Clozapine REMS Curbs Treatment: Comments

Three mental health stakeholders call on two FDA advisory committees to recommend changes to the clozapine REMS.

latest-news-card-1
Medical Devices

Zeta Gets Navigation System Improvements Cleared

FDA clears a Zeta Surgical 510(k) for its Zeta Navigation System for use with expanded instruments and enhanced hospital connectivity.

latest-news-card-1
Medical Devices

Advisors Asked for ProSense Benefits, Risks

FDA raises questions to be considered by members of its General and Plastic Surgery Advisory Committee about IceCare Medicals ProSense cryoblation sys...

latest-news-card-1
Human Drugs

Objectionable Conditions at Hospital IRB

FDA warns the Kittanning, PA-based Armstrong County Memorial Hospital IRB about objectionable conditions identified in a Bioresearch Monitoring Progra...

latest-news-card-1

FDA Cant Regulate AI on its Own: Califf

FDA commissioner Robert Califf says collaboration with external stakeholders is needed to adequately monitor and regulate artificial intelligence.

latest-news-card-1
Human Drugs

Acadia Unloads Priority Voucher for $150 Million

Acadia Pharmaceuticals sells its Rare Pediatric Disease Priority Review Voucher for $150 million.

latest-news-card-1
Medical Devices

FDA OKs Envoy Medical Cochlear Implant Study

FDA approves an Envoy Medical IDE for its pivotal study of the Acclaim Fully Implanted Cochlear Implant.

latest-news-card-1
Human Drugs

Extended Review for Organons Vtama sNDA

FDA extends by three months its review of an Organon supplemental NDA for Vtama (tapinarof) cream and its use for treating atopic dermatitis.

Human Drugs

CGMP Issues at Chinas Shandong Boyuan

FDA issues an untitled letter to Chinas Shandong Boyuan Pharmaceutical Co. about CGMP deviations in its manufacturing of active pharmaceutical ingredi...